Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ampicillin Sodium

FDA-approved product (injectable, injection), marketed as Ampicillin Sodium, Omnipen-N, Penbritin-S and 13 more.

Registered studies
50+
Lab records
69
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ampicillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial meningitis
  • Endocarditis
  • Eye infection
  • Gonorrhea
  • Infection
  • Infectious meningitis
  • Sepsis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA01; WHO ATC J01CA51; WHO ATC S01AA19

Repurposing investigation

Ampicillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 20 lab records
  • E. coli: measured active in 4 of 10 lab records
  • K. pneumoniae: measured active in 12 of 39 lab records
Open Ampicillin Sodium in ChEMBL Registered studies below
Show the 69 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ampicillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

    NCT02407119 · start 2003-06

    Registered record
    Registry ID
    NCT02407119
    Conditions
    Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Interventions
    7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2003-06
    Completion
    2030-06
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection
    Intervention7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Placebo, Omeprazole or Rabeprazole, Clarithromycin
    PhasePhase 3
    Registry statusActive not recruiting

  • Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

    NCT01792700 · start 2003-01

    Registered record
    Registry ID
    NCT01792700
    Conditions
    Helicobacter Infections
    Interventions
    esomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline; moxifloxacin; amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2010-12
    Enrolment
    648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Infections
    Interventionesomeprazole; tripotassium dicitrate bismuthate; metronidazole; tetracycline +2 more
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

    NCT00195533 · start 2001-07

    Registered record
    Registry ID
    NCT00195533
    Conditions
    Hematological Malignancy; Leukemia; Myelodysplasia; Lymphoma; Myeloma; Stem Cell Transplantation
    Interventions
    piperacillin-tazobactam; glycopeptide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2005-03
    Enrolment
    801

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy; Leukemia; Myelodysplasia; Lymphoma +2 more
    Interventionpiperacillin-tazobactam; glycopeptide
    PhaseNot recorded
    Registry statusCompleted

  • Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma

    NCT00201422 · start 1996-06

    Registered record
    Registry ID
    NCT00201422
    Conditions
    MALT Lymphoma
    Interventions
    Omeprazole, Amoxicillin, Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1996-06
    Completion
    2004-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMALT Lymphoma
    InterventionOmeprazole, Amoxicillin, Clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Acupuncture and Herbal Treatment of Chronic HIV Sinusitis

    NCT00002149

    Registered record
    Registry ID
    NCT00002149
    Conditions
    HIV Infections; Sinusitis
    Interventions
    Clavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Sinusitis
    InterventionClavulanate potassium; Pseudoephedrine hydrochloride; Amoxicillin trihydrate
    PhaseNot applicable
    Registry statusCompleted